In a world of information overload, it can feel soothing to stick your head in the sand.
Don’t want to hear what the doctor might say? It’s easy not to make a follow-up appointment. Did a favorite political candidate say something you disagreed with? The evidence can disappear with a flick of a finger.
According to psychologists, avoiding information when it’s uncomfortable is a common adult behavior, often referred to as the “Ostrich Effect.”
The future of pacemaker technologies — wade demmer — VP, R&D, medtronic.
Wade Demmer is Vice President of Research & Development at Medtronic where he is responsible for the development of new generations of pacemakers (https://www.medtronic.com/en-us/l/patients/treatments-therap…ers.html). With extensive expertise in medical technology and innovation, he leads the company’s R&D efforts to develop cutting-edge healthcare solutions and is dedicated to advancing medical advancements that improve patient outcomes and transform healthcare delivery.
Wade began his career at Intel, where he gained valuable experience in technology development and engineering. Building on his technical expertise, he transitioned into the medical device industry, bringing a strong innovation-driven mindset to healthcare solutions.
Wade is best known for his pioneering work on pacemakers, where he contributed to the design and development of advanced cardiac pacing technologies. His innovative approaches have helped improve the reliability, longevity, and patient comfort of pacemaker devices, significantly impacting the field of cardiac care.
Wade received his Bachelor of Engineering (BEng), with a focus on Computer Engineering, from Iowa State University, and his MBA from University of Minnesota Carlson School of Management.
Globally recognized figures Muhammad Ali and Michael J. Fox have long suffered from Parkinson’s disease. The disease presents a complex set of motor symptoms, including tremors, rigidity, bradykinesia, and postural instability. However, traditional diagnostic methods have struggled to sensitively detect changes in the early stages, and drugs targeting brain signal regulation have had limited clinical effectiveness.
Recently, Korean researchers successfully demonstrated the potential of a technology that integrates AI and optogenetics as a tool for precise diagnosis and therapeutic evaluation of Parkinson’s disease in mice. They have also proposed a strategy for developing next-generation personalized treatments.
A collaborative research team, comprising Professor Won Do Heo’s team from the Department of Biological Sciences, Professor Daesoo Kim’s team from the Department of Brain and Cognitive Sciences, and Director Chang-Jun Lee’s team from the Institute for Basic Science (IBS) Center for Cognition and Sociality, achieved a preclinical research breakthrough by combining AI analysis with optogenetics.
Pancreatic cancer is an aggressive disease, and unlike many other cancers, survival rates have barely improved. Researchers at Karolinska Institutet, in collaboration with the Department of Pathology at Karolinska University Hospital, have now shown that pancreatic tumor cells not only spread in the connective tissue–rich environment that is a well-known characteristic of pancreatic cancer but also grow into damaged parts of normal pancreatic tissue. There, the cancer can create its own environment.
The study, published in Nature Communications, is based on samples from 108 patients who underwent surgery at Karolinska University Hospital. In almost all cancers, tumor cells were found in the tissue that produces digestive enzymes, but it is damaged when tumor cells grow into it.
“We see that the tumor cells adapt to the environment they find themselves in. In damaged areas of normal pancreatic tissue, they exhibit different characteristics than in the connective tissue-rich part of the tumor,” says Marco Gerling, a researcher at the Department of Clinical Science, Intervention and Technology, Karolinska Institutet, who led the study together with pathologist Carlos Fernández Moro.
A new, highly potent class of immunotherapeutics with unique Velcro-like binding properties can kill diverse cancer types without harming normal tissue, University of California, Irvine cancer researchers have demonstrated.
A team led by Michael Demetriou, MD, Ph.D., has reported that by targeting cancer-associated complex carbohydrate chains called glycans with binding proteins, they could penetrate the protective shields of tumor cells and trigger their death without toxicity to surrounding tissue.
Their biologically engineered immunotherapies—glycan-dependent T cell recruiter (GlyTR, pronounced ‘glitter’) compounds, GlyTR1 and GlyTR 2—proved safe and effective in models for a spectrum of cancers, including those of the breast, colon, lung, ovaries, pancreas and prostate, the researchers report in the journal Cell.
Research published by Duke University researchers has found a strong link between higher stress in children and adverse health conditions for them later in life. Appearing in the journal Proceedings of the National Academy of Sciences, the study used measurable metrics of health over time to create a more quantitative view of how stress early in life affects health.
“We’ve had an idea for a long time, since the ’80s at least, that when children have adversity in their lives, it affects how their bodies work, not just psychologically, but also physiologically. It gets underneath the skin, and it becomes embodied in the way your body handles stress,” said co-author Herman Pontzer, Duke professor of evolutionary anthropology and global health.
Researchers focused on allostatic load (AL), which refers to the wear and tear on the body because of chronic stress. The researchers “tested associations between childhood AL and adult cardiometabolic health,” relying on biomarkers that included antibodies of C-reactive protein, which is a marker of inflammation in the body; and the Epstein-Barr virus, which is common and highly contagious; body mass index; and blood pressure.
A new study led by the Icahn School of Medicine at Mount Sinai offers one of the most comprehensive views yet of how brain cells interact in Alzheimer’s disease, mapping protein networks that reveal communication failures and point to new therapeutic opportunities.
Published online in Cell, the study analyzed protein activity in brain tissue from nearly 200 individuals.
The researchers discovered that disruptions in communication between neurons and supporting brain cells called glia—specifically astrocytes and microglia—are closely linked to the progression of Alzheimer’s disease. One protein in particular, called AHNAK, was identified as a top driver of these harmful interactions.
Schizophrenia is a chronic mental health disorder characterized by hallucinations, delusions, disorganized thinking and atypical movement or speech patterns. This psychiatric condition can be highly debilitating, and diagnosed individuals can report markedly different experiences.
Understanding the neurobiological basis of schizophrenia could be highly valuable, as it could inform the development of new interventions to reduce the risk of its emergence or treat its symptoms. The results of many neuroimaging studies carried out so far, however, were inconsistent or inconclusive, failing to clearly delineate the processes and brain regions implicated in its clinical expression.
In a recent paper published in Nature Mental Health, researchers at Taipei Medical University analyzed meta-analyses summarizing the most consistent findings of schizophrenia-related neuroimaging studies. Drawing on the results of this analysis, they developed a new theoretical model that delineates characteristic brain alterations linked to the psychiatric disorder.